The other was an ipsilateral Grade 2 ER/PR- HER2 + recurrence with associated DCIS 8 months following first surveillance CEM and 15 months following BCS where the patient did not complete recommended adjuvant therapy. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.